New China biotech GT Apeiron pairs with Exscienta on AI-fuelled drug discovery



GT Apeiron, a new artificial intelligence (AI)-driven drug development company, has been established in Shanghai with USD 27 million in financial backing from GT Healthcare Capital Partners, a Chinese private equity fund, and other investors. At the same time, Apeiron has struck an R&D partnership with the UK-based Exscientia, a world leader in applying AI technologies to drug discovery.

According to the press release, Apeiron will focus on novel drug development, accelerated via Exscientia’s automated AI discovery platform, aiming for new pathways and high impact therapeutic targets, particularly in the field of oncology. Exscientia’s platform, dubbed Centaur Chemist, consists of a data integration engine and an automated modeling and active learning engine. This allows new molecules to be assessed for potency, selectivity, and ability to bind to specific targets and also rapidly alter the design and test new candidates toward the desired criteria. The firm’s existing partners include Roche, Celgene, GSK, Sanofi, and Evotec.


Reference:

Related news
China-based biotechs Tot Biopharm Co., Ltd, and Shanghai Junshi Biosciences Co., Ltd, (HKX.1877) agreed to pair Tot's TAB008, a biosimilar of Roche’s anti-VEGF monoclonal antibody (mAb) bevacizumab (Avastin), in combination with Junshi Bio’s toripalimab (JS001), an innovative recombinant human programmed death-1 (PD-1) monoclonal antibody (mAb).
BeiGene Ltd (Nasdaq.BGNE; HKEX.06160)’s partnership with US major Celgene Corporation has formally drawn to a close, after the Beijing-based biotech announced that it has regained full global rights to the programmed death-1 (PD-1) inhibitor tislelizumab.
Chinese biotech Zai Lab picked up another market approval for Zejula (niraparib), following up the October 2018 nod received in Hong Kong with approval to commercialize in Macau.
  • 1560391618086
  • China
  • Drug
Three China-based firms announced the successful completion of generic quality and consistency evaluation (GQCE) work for three products.
Brazil-based laboratory Libbs Farmacêutica’s Vivaxxia this week became the first locally manufactured rituximab biosimilar to obtain approval from the country’s National Health Surveillance Agency (ANVISA), GBI analysis reveals.
Recent news
Nelson Mussolini, head of Brazil’s Industry Syndicate of Pharmaceutical Products (SINDUSFARMA) and member of the National Health Council, this week voiced his position against the government’s control of drug prices and the high tax rates.
The Center for State Control of Drugs and Medical Devices (CECMED) last week cleared Catalonia (Spain)-based Laboratorio Estedi’s Ursobilane (ursodeoxycholic acid) for the Cuba market, GBI analysis reveals.
According to GBI analysis, Peru’s General Directorate of Medicines, Supplies and Drugs (DIGEMID) this week granted marketing authorization to Japan-based Otsuka Pharmaceutical’s drug-resistant tuberculosis (TB) treatment Deltyba (delamanid).
China-based Sino Biopharmaceutical Ltd (HKEX.01177) announced the signing of a joint venture (JV) agreement between its subsidiary Chia Tai Tianqing Pharmaceutical Group Co., Ltd, and Akeso Biopharma Inc​.
A team of Chinese scientists led by Professor Ma Xiong, from Renji Hospital Affiliated to Shanghai Jiaotong University School of Medicine (Renji Hospital)'s gastroenterology department, has uncovered the characteristics of intestinal flora in patients with autoimmune hepatitis (AIH), according to the hospital.
  • 1560834410023
  • China
  • R&D
China-based biotechs Tot Biopharm Co., Ltd, and Shanghai Junshi Biosciences Co., Ltd, (HKX.1877) agreed to pair Tot's TAB008, a biosimilar of Roche’s anti-VEGF monoclonal antibody (mAb) bevacizumab (Avastin), in combination with Junshi Bio’s toripalimab (JS001), an innovative recombinant human programmed death-1 (PD-1) monoclonal antibody (mAb).
Colombia’s National Food and Drug Surveillance Institute (INVIMA) this week issued marketing approval to Johnson & Johnson (J&J) subsidiary Janssen’s oral cancer drug Erleada (apalutamide).
Analytics Snapshot